Full text is available at the source.
Abstract
The association between GLP-1 receptor agonist use and pancreatic cancer risk remains uncertain.
- GLP-1 receptor agonists are commonly used in treating type 2 diabetes and obesity.
- Prior observational studies have produced conflicting evidence regarding the risk of pancreatic cancer in users of GLP-1 receptor agonists.
- This evaluation aims to compare the risk of pancreatic cancer for patients starting GLP-1 receptor agonist therapy with those using six other classes of antidiabetic medications.
Simplified